Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patients

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with poor prognosis and limited benefit from immune checkpoint inhibitors (ICIs). Biomarker-driven patient stratification has been hindered by small biopsy samples, high tumor heterogeneity, and the limited predictive value of PD-L1...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Luisa Amato, Ines Tavoletta, Caterina De Rosa, Mimimorena Seggio, Francesco Arcadio, Sara Capaldo, Faiz Ul Haq, Concetta Tuccillo, Carla Esposito, Gaetano di Guida, Francesca Iommelli, Viviana De Rosa, Alfonso Reginelli, Salvatore Cappabianca, Floriana Morgillo, Fortunato Ciardiello, Valerio Nardone, Nunzio Cennamo, Carminia Maria Della Corte, Luigi Zeni
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-05-01
Serie:	Translational Oncology
Soggetti:	SCLC Blood-based biomarker Liquid biopsy MAVS Immune sensing
Accesso online:	http://www.sciencedirect.com/science/article/pii/S1936523326000938
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!